Mediaboss Marketing

Story Links

The Division III Strategic Planning and Finance Committee met Tuesday in Indianapolis for discussions around key strategic and budget issues.

The committee approved a motion to send a formal recommendation to the Management and Presidents Councils to hire an outside vendor to evaluate Division III's Enrichment Fund programs and initiatives and determine whether the program outcomes align with the division's strategic priorities. Both councils supported the initial idea of an assessment in October 2022.

The evaluation would include all grants and programs currently being funded through the Enrichment Fund. Currently, the Enrichment Fund provides grants and programs in the following areas:

"As fierce supporters of Division III athletics and the role it serves at our institutions, the topics we covered in our Strategic Planning and Finance Committee meeting are crucial to the continued vitality of the division," said Jim Troha, chair of the committee, vice chair of the Presidents Council and president at Juniata.

After discussions at the 2023 NCAA Convention among the Management and Presidents Councils, the committee discussed the newly created Financial and Risk Management Working Group. It noted the working group will collaborate with the Strategic Planning and Finance Committee andbe responsible for reviewing the landscape of intercollegiate athletics, the division's financial standing, and the risks, threats and opportunities that confront the division.As needed, the working group will prepare alternatives for the Presidents Council to act on behalf of the division.

The committee also discussed Division III's review of its philosophy statement, using feedback from the Issues Forum at the NCAA Convention and recent meetings of the Philosophy Statement Review Working Group.

The focus of the conversation centered around the need for the philosophy statement to account for how the division has changed and provide adequate flexibility for its continued evolution.

The Strategic Planning and Finance Committee reviewed the latest draft and will forward it to the Management and Presidents Councils to provide feedback during their April meetings. After the councils' review, the working group will share the latest draft with the membership for feedback. The committee's goal is to review a final draft during its June meeting to forward to the councils to consider sponsoring a legislative proposal for the 2024 NCAA Convention to establish a new Division III philosophy statement.

The new CBS/Turner Sports broadcast agreement begins in fiscal year 2025, and Division III will receive a 13% revenue increase. With the additional funds coming, the committee received an update from the chair of the Championships Committee regarding discussions to enhance the student-athlete championship experience. Topics up for conversation include equal access to Pool C (at large), providing additional flights during opening rounds to protect higher regional seeds and/or providing more funding to the current championship experience.

The Championships Committee will be seeking feedback from the membership, via a survey to be distributed in April, regarding these potential championships enhancements.

See the original post here:
DIII Strategic Planning and Finance Committee recommends ... - NCAA.org

There are yet-to-be-released evaluation and management (E/M) changes on the way in 2024 and 2025, according to theCPT Editorial Summary of Panel Actions, which the AMA also published earlier this month.

But for now, there are many recent changes to this code set that your outpatient coding teams should be aware of.

As revenue cycle leaders know, coding challenges can easily lead to delays in reimbursement. When the coding process is hindered, the revenue cycle can be slowed by a backlog of charts, errors in claims, or working denials, which is why staying up to date on even the most minute changes is essential.

When it comes to recent updates, there are two small but important changes (in bold below) in the2023 CPT Manualsection Amount and/or Complexity of Data to be Reviewed and Analyzed:

Independent interpretation: The interpretation of a test for which there is a CPT code, and an interpretation or report is customary. This does not apply when the physician or other qualified healthcare professional who reports the E/M service is reporting or has previously reported the test. A form of interpretation should be documented but need not conform to the usual standards of a complete report for the test.A test that is ordered and independently interpreted may count both as a test ordered and interpreted.

Appropriate source: For the purpose of the discussion of management data element (see Table 1, Levels of MDM), an appropriate source includes professionals who are not healthcare professionals but may be involved in the management of the patient (e.g., lawyer, parole officer, case manager, teacher). It does not include discussion with family or informal caregivers.For the purpose of documents reviewed, documents from an appropriate source may be counted.

The most recent CPT erratas clarification regarding the counting of data elements is a bit surprising, Shannon McCall, director of HIM and coding at HCPro, told Part B News.

According to Part B News, allowing the order of a unique test and the independent interpretation of that same test to be counted separately could make it easier to classify data complexity as moderate for many encounters in the inpatient, observation, and emergency department (ED) settings.

In EDs, especially after hours, it is not uncommon for multiple tests (imaging, labs, etc.) to be ordered and those orders may very well include ones that are eligible for independent interpretation, McCall said.

Coders should remember that To classify overall MDM, another of the two elements (number and complexity of problems addressed or risk of morbidity) must also be met, McCall adds, It would seem quite easy for EDs, since prescription drug management is likely a component of the services provided for many patients.

This could increase reporting of ED codes99284(ED visit for the E/M of a patient, which requires a medically appropriate history and/or examination and moderate level of MDM) and99285 (ED visit for the E/M of a patient, which requires a medically appropriate history and/or examination and high level of MDM), McCall said in the interview.

Amanda Norris is the Revenue Cycle Editor for HealthLeaders.

View original post here:
Safeguard Reimbursement: Coding Teams to See Outpatient ... - HealthLeaders Media

The City of West Hollywoods Rent Stabilization Division will host four upcoming virtual trainings for landlords on how to register non-rent-controlled properties and units using the City websites online Landlord Service Portal.

All properties in the City not subject to rent control must be registered, and all new tenancies at those properties must be re-registered within 30 days of the re-rental. Landlords are encouraged to attend one of the following virtual webinars:

These virtual trainings for landlords on registering non-rent-controlled properties and units are free and open to the community. Details and information for each meeting, including Zoom meeting links, is available on the City of West Hollywood website calendar at http://www.weho.org/calendar. Complete information regarding the new registration and re-registration requirements can be found on the Citys website at http://www.weho.org/city-government/rent-stabilization/rental-housing/for-property-owners/non-rso-unit-registry.

Requests for language translation for virtual trainings must be received a minimum of 72 hours before each workshop. For landlords or their representatives who cannot attend a webinar, recorded trainings will be made available on the Citys website for use at any time.

The Citys adoption of Ordinance No. 22-1177 added Section 17.28.050 to the West Hollywood Municipal Code, requiring that, beginning in 2023, most properties with rental units that are not subject to rent control under the Rent Stabilization Ordinance also follow the registration and re-registration process. This includes all multi-family residential rental properties built after July 1, 1979 and any rented condominium or single-family residence.

The online Landlord Service Portal for initial registration of non-rent-controlled properties and units will be available starting Tuesday, April 4, 2023, and landlords must complete the registration process within 30 days of that date. Once a property is registered, the landlord will have an ongoing obligation to re-register new tenancies as they are created.

The City of West Hollywoods Rent Stabilization Division is dedicated to programs that promote the quality of residential life a core value of the City of West Hollywood. The City provides a breadth of information and services to tenants, owners, and property managers of residential rental properties, which includes information services and written materials. For additional information, please visit http://www.weho.org/rsd.

For more information and to RSVP for upcoming virtual trainings for landlords, please contact Roger Vinalon, Jr., City of West Hollywood Administrative Specialist, at rvinalon@weho.org or at (323) 848-6438. For people who are Deaf or hard of hearing, please call TTY (323) 848-6496.

For up-to-date information about City of West Hollywood news and events, follow @wehocity on social media, sign-up for news updates at http://www.weho.org/email, and visit the Citys calendar of meetings and events at http://www.weho.org/calendar. The City of West Hollywood remains in a declared local emergency in response to the coronavirus (COVID-19) pandemic. West Hollywood City Hall is open for walk-in services at public counters or by appointment by visiting http://www.weho.org/appointments. City Hall services are accessible by phone at (323) 848-6400 and via website at http://www.weho.org. The Citys coronavirus updates are available at http://www.weho.org/coronavirus.

For reporters and members of the media seeking additional information about the City of West Hollywood, please contact the City of West Hollywoods Public Information Officer, Sheri A. Lunn, at (323) 848-6391 or slunn@weho.org.

Read more from the original source:
will Host Virtual Workshops on How to Comply with Mandatory ... - City of West Hollywood

Released on March 22, 2023

This year's Agriculture Budget is $548.2 million, a 19 per cent increase from the previous year, with a strong investment in programs, services and agriculture research, as well as a fully-funded suite of business risk management programs.

"Supported by this year's budget, the industry is well-positioned to continue to take on the challenges inherent to agriculture and build on their success," Agriculture Minister David Marit said. "This budget will help Saskatchewan's farmers, ranchers and agri-business remain competitive and operate sustainably while continuing to deliver safe, high-quality food."

The 2023-24 Agriculture Budget contains $89.8 million for strategic initiatives under the federal-provincial Sustainable Canadian Agricultural Partnership, which will launch in the new fiscal year. The budget provides increased support for producers to develop sustainable agriculture water sources like wells, dugouts and pipelines, as well as increased funding for irrigation programming.

The budget includes $1.0 million to target invasive weed control on agricultural Crown land pastures, promoting continued productivity and stewardship of this resource and more than $38 million for agricultural research.

There is $408 million to fund a suite of federal-provincial risk management programs including Crop Insurance and AgriStability. Average Crop Insurance coverage for 2023 is at a record-high level of $446 per acre due to increased commodity prices and yield coverage. The AgriStability compensation rate will increase from 70 to 80 per cent for the 2023 program year, to better support farmers in times of need.

Saskatchewan producers harvested a crop of nearly 35 million tonnes in 2022, with record agri-food exports valued at $18.4 billion.

-30-

For more information, contact:

Continue reading here:
Agriculture Budget Supports Innovative, Sustainable and ... - Government of Saskatchewan

AstraZenecas Calquence (acalabrutinib), a next generation, selective Brutons tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This is the first approved indication for Calquence in China.

The conditional approval by the National Medical Products Administration (NMPA) was based on positive results from two clinical trials, including the ACE-LY-004 global Phase II trial in adults with relapsed or refractory MCL and a Phase I/ II trial in Chinese patients with relapsed or refractory MCL and other B-cell malignancies.1,2 Continued approval for this indication may be contingent upon verification of ongoing randomised controlled confirmatory trials.

MCL is typically an aggressive, rare form of non-Hodgkin lymphoma (NHL) that accounts for between 2-6% of all patients diagnosed with NHL in China. Patients are generally diagnosed around 60years of age, often at later stages of the disease.3

Jun Zhu, Chief Physician, Department of Lymphatic Oncology, Peking University Cancer Hospital, Beijing, said: Mantle cell lymphomaprogresses rapidly and responds poorly to conventional treatmentsuch as immunochemotherapy.Before the emergence of BTK inhibitors, there were few satisfactory treatment options forpatients.The next-generation BTK inhibitor Calquence has higher target selectivity, fewer side effects, and a higher response rate compared to currently available treatments. This approval of Calquence in China can provide a new treatment option which can better benefit patients with this disease.

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: This approval for Calquence offers people living with mantle cell lymphoma in China an effective and tolerable new treatment option to help control their disease. As the first approval in China for Calquence, it is also an exciting step forward for AstraZeneca in blood cancers, enabling us to help more patients across the globe gain access to innovative treatments.

Results from the ACE-LY-004 Phase II trial showed at a median follow up of 15.2 months, investigator-assessed overall response rate (ORR) with Calquence was 80.6% (95% confidence interval [CI] 72.6-87.2), with a complete response (CR) achieved in 39.5% of patients with relapsed or refractory MCL (95% CI 30.9-48.7).1 Longer-term follow-up data showed at 38.1 months, patients treated with Calquence remained progression-free for a median of 22 months, with median overall survival (OS) of 59.2 months (95% CI 36.5-NE).4

Additionally, results from a Phase I/II trial conducted in China showed Calquence achieved a 82.4% ORR, with a CR achieved in 35.3% of patients with MCL based on a blinded independent central-review (BICR) analysis (95% CI 65.5-93.2). Calquence reduced the risk of disease progression or death by 51.5% (95% CI 33.3-67.0) at 12 months, with an estimated duration of response (DOR) of 65.5% (95% CI 66.6-93.3). The median DOR was not reached.2

The safety and tolerability of Calquence in these trials was consistent with that observed in previous clinical trials.1,2,4

Calquenceis approvedfor the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the US and Japan and is approved for the treatment of CLL in the EU and in several other countries worldwide in the treatment-nave and relapsed or refractory settings.Calquenceis also approved in the US and several other countries for the treatment of adult patients with MCL who have received at least one prior therapy. Calquenceis not currently approved for the treatment of MCL in Japan or the EU.

Notes

Mantle cell lymphoma (MCL)MCL is a rare B-cell malignancy subtype and is typically clinically aggressive with a poor prognosis.3The epidemiology of MCL in Asia is not well documented, with few published datasets describing the incidence and outcomes.3MCL accounts for between 2-6% of all patients diagnosed with NHL China.3Patients are generally diagnosed around 60years of age and often at later stages of disease (Stage III or IV).3

ACE-LY-004ACE-LY-004 is an open-label, single-arm Phase II clinical trial evaluating Calquence in adult patients with relapsed or refractory MCL.5 Patients in the trial were adults with MCL and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or lower who had relapsed or were refractory to 1-5 prior therapies, had no prior BTK/BCL-2 inhibitor exposure, and did not require warfarin/vitamin K antagonists. Patients received oral Calquence 100mg twice-daily until progressive disease or toxicity. ORR (investigator-assessed partial response or better per Lugano classification), DOR, progression-free survival (PFS), OS and safety were assessed.1

Phase I/II trial in Chinese patientsThe Phase I/II trial is an open-label, multicentre clinical trial evaluatingpharmacokinetics, safety and efficacy ofCalquencein adult Chinese patients with relapsed or refractory MCL and other advanced B-cell malignancies.2In Phase I, patients with relapsed or refractory B-cell malignancies received a single dose ofCalquence100mg orally followed by a two-day washout period and subsequent treatment withCalquence100mg orally twice daily in 28-day cycles, until progressive disease (PD) or treatment discontinuation (TD) for any other reason. In Phase II, patients with relapsed or refractory MCL and ECOG status of 2 or lower receivedCalquence100mg orally twice daily in 28-day cycles until PD or TD. The primary efficacy endpoint was ORR per Lugano classification for NHL assessed by BICR. Secondary endpoints were investigator-assessed ORR, BICR- and investigator-assessed time to response, DOR, PFS, OS and adverse events.2

CalquenceCalquence(acalabrutinib) is a next-generation, selective inhibitor of BTK.Calquencebinds covalently to BTK, thereby inhibiting its activity.6In B cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis and adhesion.

Calquenceis approved for the treatment of CLL and SLL in the US, approved for CLL in the EU and many other countries worldwide and approved in Japan for relapsed or refractory CLL and SLL.

As part of an extensive clinical development programme,AstraZeneca is currently evaluating Calquencein more than 20 company-sponsored clinical trials. Calquence is being evaluated for the treatment of multiple B-cell blood cancers, including CLL, MCL, diffuse large B-cell lymphoma, Waldenstrms macroglobulinaemia, marginal zone lymphoma and other haematologic malignancies.

AstraZeneca in haematologyAstraZeneca is pushing the boundaries of science to redefine care in haematology. We have expanded our commitment to patients with haematologic conditions, not only in oncology but also in rare diseases with the acquisition of Alexion, allowing us to reach more patients with high unmet needs. By applying our deep understanding of blood cancers, leveraging our strength in solid tumour oncology and delivering on Alexions pioneering legacy in complement science to provide innovative medicines for rare diseases, we are pursuing the end-to-end development of novel therapies designed to target underlying drivers of disease.

By targeting haematologic conditions with high unmet medical needs, we aim to deliver innovative medicines and approaches to improve patient outcomes. Our goal is to help transform the lives of patients living with malignant, rare and other related haematologic diseases, shaped by insights from patients, caregivers and physicians to have the most meaningful impact.

AstraZeneca in oncologyAstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Companys focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZenecaAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visitastrazeneca.comand follow the Company on Twitter@AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Read more:
Calquence granted first regulatory approval in China for adults with ... - AstraZeneca